JP4389271B2 - N−ヒドロキシホルムアミジン誘導体 - Google Patents
N−ヒドロキシホルムアミジン誘導体 Download PDFInfo
- Publication number
- JP4389271B2 JP4389271B2 JP2004535940A JP2004535940A JP4389271B2 JP 4389271 B2 JP4389271 B2 JP 4389271B2 JP 2004535940 A JP2004535940 A JP 2004535940A JP 2004535940 A JP2004535940 A JP 2004535940A JP 4389271 B2 JP4389271 B2 JP 4389271B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- added
- formula
- mmol
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IONSZLINWCGRRI-UHFFFAOYSA-N n'-hydroxymethanimidamide Chemical class NC=NO IONSZLINWCGRRI-UHFFFAOYSA-N 0.000 title claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000000532 dioxanyl group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 34
- 239000000203 mixture Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- -1 for example Chemical group 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 0 CC1([*-])CCCC1 Chemical compound CC1([*-])CCCC1 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- RGUOJYYIMVSCNC-UHFFFAOYSA-N n,n-dimethylformamide;2-methylpropanoic acid Chemical compound CN(C)C=O.CC(C)C(O)=O RGUOJYYIMVSCNC-UHFFFAOYSA-N 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- PYUABAXAUVLRNX-UHFFFAOYSA-N dimethyl 2-(4-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C([N+]([O-])=O)C=C1 PYUABAXAUVLRNX-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- TVXJZSLWDKYLMS-UHFFFAOYSA-N n'-[4-[2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl]phenyl]-n-hydroxymethanimidamide Chemical compound O1CC(C)(C)COC1CCC1=CC=C(NC=NO)C=C1 TVXJZSLWDKYLMS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- CKEUDZGWGCUHLX-UHFFFAOYSA-N 1-[3-(2-methoxyethoxy)propyl]-4-nitrobenzene Chemical compound COCCOCCCC1=CC=C([N+]([O-])=O)C=C1 CKEUDZGWGCUHLX-UHFFFAOYSA-N 0.000 description 2
- ALGQVMMYDWQDEC-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enal Chemical compound [O-][N+](=O)C1=CC=C(C=CC=O)C=C1 ALGQVMMYDWQDEC-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- NYUOVICEZDPRBR-UHFFFAOYSA-N 3-(dimethylamino)-2,2-dimethylpropanal Chemical compound CN(C)CC(C)(C)C=O NYUOVICEZDPRBR-UHFFFAOYSA-N 0.000 description 2
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 2
- HANWYXNPIUDOGZ-UHFFFAOYSA-N 4-[3-(2-methoxyethoxy)propyl]aniline Chemical compound COCCOCCCC1=CC=C(N)C=C1 HANWYXNPIUDOGZ-UHFFFAOYSA-N 0.000 description 2
- ZTNHTALUTWMBDS-UHFFFAOYSA-N 4-[4-(diethylamino)butyl]aniline Chemical compound CCN(CC)CCCCC1=CC=C(N)C=C1 ZTNHTALUTWMBDS-UHFFFAOYSA-N 0.000 description 2
- JQKNARUEQPFUHL-UHFFFAOYSA-N 4-[4-(dimethylamino)-3,3-dimethylbutyl]aniline Chemical compound CN(C)CC(C)(C)CCC1=CC=C(N)C=C1 JQKNARUEQPFUHL-UHFFFAOYSA-N 0.000 description 2
- GTOQFZRKJXXOTO-UHFFFAOYSA-N 5,5-dimethyl-2-[2-(4-nitrophenyl)ethenyl]-1,3-dioxane Chemical compound O1CC(C)(C)COC1C=CC1=CC=C([N+]([O-])=O)C=C1 GTOQFZRKJXXOTO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- AIPRAPZUGUTQKX-UHFFFAOYSA-N diethoxyphosphorylmethylbenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1 AIPRAPZUGUTQKX-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- DICCCUJWYKQLFU-UHFFFAOYSA-N n,n,2,2-tetramethyl-4-(4-nitrophenyl)butan-1-amine Chemical compound CN(C)CC(C)(C)CCC1=CC=C([N+]([O-])=O)C=C1 DICCCUJWYKQLFU-UHFFFAOYSA-N 0.000 description 2
- CMCNZKMJVZUHDJ-UHFFFAOYSA-N n,n,2,2-tetramethyl-4-phenylbut-3-en-1-amine Chemical compound CN(C)CC(C)(C)C=CC1=CC=CC=C1 CMCNZKMJVZUHDJ-UHFFFAOYSA-N 0.000 description 2
- RCHLXQYTVKMURJ-UHFFFAOYSA-N n,n,2,2-tetramethyl-4-phenylbutan-1-amine Chemical compound CN(C)CC(C)(C)CCC1=CC=CC=C1 RCHLXQYTVKMURJ-UHFFFAOYSA-N 0.000 description 2
- NGJSGVFTNZDFIC-UHFFFAOYSA-N n,n-diethyl-4-(4-nitrophenyl)butan-1-amine Chemical compound CCN(CC)CCCCC1=CC=C([N+]([O-])=O)C=C1 NGJSGVFTNZDFIC-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- XBGNOMBPRQVJSR-UHFFFAOYSA-N 2-(4-nitrophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=C([N+]([O-])=O)C=C1 XBGNOMBPRQVJSR-UHFFFAOYSA-N 0.000 description 1
- XMMRNCHTDONGRJ-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C([N+]([O-])=O)C=C1 XMMRNCHTDONGRJ-UHFFFAOYSA-N 0.000 description 1
- IQQYLBIFFAFHPD-UHFFFAOYSA-N 3-(iminomethylideneamino)propan-1-amine;hydrochloride Chemical compound Cl.NCCCN=C=N IQQYLBIFFAFHPD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WQMLUHZFRFCQDB-UHFFFAOYSA-N 4-(4-nitrophenyl)butyric acid Chemical compound OC(=O)CCCC1=CC=C([N+]([O-])=O)C=C1 WQMLUHZFRFCQDB-UHFFFAOYSA-N 0.000 description 1
- WQLBSJLKMDHRCB-UHFFFAOYSA-N 4-[2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl]aniline Chemical compound O1CC(C)(C)COC1CCC1=CC=C(N)C=C1 WQLBSJLKMDHRCB-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QEGNUYASOUJEHD-UHFFFAOYSA-N CC1(C)CCCCC1 Chemical compound CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 1
- LETYIFNDQBJGPJ-UHFFFAOYSA-N CCC1(C)CCCC1 Chemical compound CCC1(C)CCCC1 LETYIFNDQBJGPJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- AXZMZCSMQAXFEK-UHFFFAOYSA-N N.N.[Ce+4] Chemical compound N.N.[Ce+4] AXZMZCSMQAXFEK-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MXOQNVMDKHLYCZ-UHFFFAOYSA-N benzamidoxime Chemical class ON=C(N)C1=CC=CC=C1 MXOQNVMDKHLYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- LWJYMKDMGMOTSB-UHFFFAOYSA-L dichlorotin;hydrate Chemical compound O.Cl[Sn]Cl LWJYMKDMGMOTSB-UHFFFAOYSA-L 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- AOQZRLPQXSPPNG-UHFFFAOYSA-N dimethyl 2-[2-(2-methoxyethoxy)ethyl]-2-(4-nitrophenyl)propanedioate Chemical compound COCCOCCC(C(=O)OC)(C(=O)OC)C1=CC=C([N+]([O-])=O)C=C1 AOQZRLPQXSPPNG-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- PFBQVGXIMLXCQB-VMPITWQZSA-N ethyl (e)-3-(4-nitrophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 PFBQVGXIMLXCQB-VMPITWQZSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- WKJJUGSWNSGLEN-UHFFFAOYSA-N n'-[4-(3,3-dimethyl-4-pyrrolidin-1-ylbutyl)phenyl]-n-hydroxymethanimidamide Chemical compound C1CCCN1CC(C)(C)CCC1=CC=C(NC=NO)C=C1 WKJJUGSWNSGLEN-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZKLFHPAZZJBQAQ-UHFFFAOYSA-N n-hydroxy-n'-[4-[3-(2-methoxyethoxy)propyl]phenyl]methanimidamide Chemical compound COCCOCCCC1=CC=C(NC=NO)C=C1 ZKLFHPAZZJBQAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明者らは前記課題を解決する目的で鋭意探索研究した結果、ある特異な部分構造を有する芳香族化合物、すなわちN−(4−アルキル置換フェニル)−N'−ヒドロキシホルムアミジン誘導体が意外にも選択的に20−HETEの産生酵素の阻害作用を有することを見出し、本発明を完成した。すなわち、本発明は、下記式
他の本発明は、20−HETEの産生酵素の阻害剤であるN−ヒドロキシホルムアミジン誘導体を提供するものである。
本発明において使用される用語が以下に定義される。
C1-4アルキル基は、炭素原子を1〜4個有する直鎖状又は分枝状のアルキル基を意味し、例えば、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基などが挙げられる。C1-4アルコキシ基は、炭素原子を1〜4個有する直鎖状又は分枝状のアルコキシ基を意味し、例えば、メトキシ基、エトキシ基、n−プロポキシ基、イソプロポキシ基、n−ブトキシ基などが挙げられる。
式
C1-4アルキル基で置換されたジオキサニル基は、その基の環がC1-6アルキル基で置換されていてもよく、例えば、5,5−ジメチル−1,3−ジオキサン−2−イル基などである。
式
また、製薬学的に許容される塩とは、アルカリ金属類、アルカリ土類金属類、アンモニウム、アルキルアンモニウムなどとの塩、鉱酸又は有機酸との塩であり、例えば、ナトリウム塩、カリウム塩、カルシウム塩、アンモニウム塩、アルミニウム塩、トリエチルアンモニウム塩、酢酸塩、プロピオン酸塩、酪酸塩、ぎ酸塩、トリフルオロ酢酸塩、マレイン酸塩、酒石酸塩、クエン酸塩、ステアリン酸塩、コハク酸塩、エチルコハク酸塩、ラクトビオン酸塩、グルコン酸塩、グルコヘプトン酸塩、安息香酸塩、メタンスルホン酸塩、エタンスルホン酸塩、2−ヒドロキシエタンスルホン酸塩、ベンゼンスルホン酸塩、パラトルエンスルホン酸塩、ラウリル硫酸塩、リンゴ酸塩、アスパラギン酸塩、グルタミン酸塩、アジピン酸塩、システインとの塩、N−アセチルシステインとの塩、塩酸塩、臭化水素酸塩、リン酸塩、硫酸塩、よう化水素酸塩、ニコチン酸塩、シュウ酸塩、ピクリン酸塩、チオシアン酸塩、ウンデカン酸塩、アクリル酸ポリマ−との塩、カルボキシビニルポリマ−との塩などを挙げることができる。
製造法1
Mannich反応を利用して合成したアルデヒド1とベンジルホスホン酸ジエチル等のHorner−Emons試薬を、適当な溶媒(テトラヒドロフラン、エ−テル、トルエン、N,N−ジメチルホルムアミド等)中、適当な塩基(n−ブチルリチウム、トリエチルアミン、N,N−ジイソプロピルエチルアミン、水素化ナトリウム、ナトリウムメトキシド、t−ブトキシカリウム等)の存在下、−78℃〜室温にて1〜24時間反応し、化合物2を製造することができる。次に、化合物2とパラジウム活性炭、水酸化パラジウム等の触媒の存在下、適当な溶媒(メタノ−ル、エタノ−ル、プロパノ−ル、テトラヒドロフラン、ジオキサン、トルエン、塩化メチレン、クロロホルム、アセトニトリル、酢酸エチル等)中、水素雰囲気下で反応し、化合物3を製造することができる。次に、化合物3を発煙硝酸−濃硫酸、硝酸カリウム−濃硫酸、又は硝酸2アンモニウムセリウム(IV)−濃硫酸、等の条件でニトロ化し、ニトロ誘導体4を製造することができる。次に、化合物4を適当な溶媒(メタノ−ル、エタノ−ル、プロパノ−ル、テトラヒドロフラン、ジオキサン、トルエン、塩化メチレン、クロロホルム、アセトニトリル、酢酸エチル等)中、還元剤(パラジウム活性炭/水素雰囲気下、パラジウム活性炭/ヒドラジン水和物、パラジウム活性炭/ぎ酸アンモニウム、塩化スズ(II)1水和物、鉄/塩化アンモニウム、ラネ−ニッケル/ヒドラジン水和物等、好ましくはパラジウム活性炭/水素雰囲気下)を用いてニトロ基を還元することでアニリン誘導体5を製造することができる。
製造法2
文献(Org Letter 第4巻、第1951項、2002年)に記載された方法に準じて合成した式
で示される化合物のWolff-Kishner反応等による還元もしくは、文献(Tetrahedron、第46巻、第2111項、1990年)に記載された方法に準じて合成した、式
製造法3
発明を実施するための最良の形態
以下、実施例を挙げて本発明を更に詳しく説明する。
N−[4−(4−N,N−ジメチルアミノ−3,3−ジメチル−ブチル)フェニル]−N'−ヒドロキシフォルムアミジンの製造
(1)塩酸ジメチルアミン(10.8g, 0.132mol)と2−プロパノ−ル(62ml)の混合物にパラホルムアルデヒド(8.7g)とイソブチルアルデヒド(12ml, 0.132mol)を加えた。反応混合物を加熱還流下、一中夜攪拌した。室温に冷却した後に、反応液を濃縮した。残査に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチル(100ml×5)で抽出した。合わせた有機層を無水硫酸マグネシウムで乾燥、減圧濃縮し、3−ジメチルアミノ−2,2−ジメチルプロピオンアルデヒド(8.4 g)を無色油状物質として得た。
N−[4−(4−N,N−ジエチルアミノ−3,3−ジメチル−ブチル)フェニル]−N'−ヒドロキシフォルムアミジンの製造
実施例1と同様な方法を用いて標題化合物を合成した。
N−[4−(4−ピロリジン−1−イル−3,3−ジメチル−ブチル)フェニル]−N'−ヒドロキシフォルムアミジンの製造
実施例1と同様な方法を用いて標題化合物を合成した。
N−[4−(4−N,N−ジエチルアミノブチル)フェニル]−N’−ヒドロキシフォルムアミジンの製造
(1)4−(4−ニトロフェニル)酪酸(1.0g, 4.78mmol)とジエチルアミン(0.699g, 9.56mmol)のN,N−ジメチルホルムアミド(10ml)溶液にN−エチル−N'−3−ジメチルアミノプロピルカルボジイミド塩酸(1.37g, 7.17mmol)と1−ヒドロキシベンゾトリアゾ−ル1水和物(0.969g, 7.17mmol)を加え室温にて24時間攪拌した。反応液に水を加え、酢酸エチルで2回抽出した。合わせた有機層を飽和炭酸水素ナトリウム水溶液で洗い、無水硫酸マグネシウムで乾燥後、減圧濃縮し、N,N−ジエチル−4−(4−ニトロフェニル)ブチルアミド(1.4 g)を淡黄色油状物質として得た。
N−[4−[3−(2−メトキシエトキシ)プロピル]フェニル]−N'−ヒドロキシホルムアミジンの製造
(1)トリフェニルホスフィン(4.81 g, 18.3 mmol)のテトラヒドロフラン(20 ml)溶液に、0℃に冷却後、ジエチルアゾジカルボキシレ−ト(40% トルエン溶液;7.99 g, 18.3 mmol)とジエチレングリコ−ル モノメチルエ−テル(2.21 g, 18.4 mmol)を順次加えた。室温まで昇温し、30分間攪拌した。再び0℃に冷却し、2−(4−ニトロフェニル)マロニックアシッド ジメチルエステル(3.10 g, 12.2 mmol)のテトラヒドロフラン溶液(50 ml)を滴下した。室温まで昇温後、室温で一晩攪拌し、次いで60℃で5.5時間反応させた。反応混合物に酢酸エチルを加え、飽和食塩水で洗浄後、無水硫酸マグネシウムで乾燥した。減圧濃縮して得られた残査をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=4:1〜2:1)、次いでNHシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=4:1)で精製し、2−[2−(2−メトキシエトキシ)エチル]−2−(4−ニトロフェニル)マロニックアシッド ジメチルエステル(1.80 g)を淡黄色油状物質として得た。
N−[4−[6−(N,N−ジメチルアミノ)ヘキシル]フェニル]−N'−ヒドロキシホルムアミジンの製造
ジエチレングリコ−ル モノメチルエ−テルの代わりに5−(N,N−ジメチルアミノ)ペンタノールを出発原料に用いて実施例5と同様な方法にて標題化合物を合成した。
実施例7
N−[4−[2−(5,5−ジメチル−[1,3]ジオキサン−2−イル)エチル]フェニル]−N'−ヒドロキシホルムアミジンの製造
(1)エチル 4−ニトロシンナメ−ト(3.18 g, 14.4 mmol)のテトラヒドロフラン(30 ml)溶液に、−78℃で水素化ジイソブチルアルミニウム(1.0 Mトルエン溶液;14.4 ml,14.4mmol)を滴下し、−78℃でそのまま1時間攪拌した。さらに水素化ジイソブチルアルミニウム(1.0Mトルエン溶液;28.7 ml, 28.7 mmol)を加え、−78℃で30分間反応させた。反応液に1M塩酸水溶液を徐々に加え、酢酸エチルで抽出し、有機層を無水硫酸マグネシウムで乾燥した。減圧濃縮後、得られた残査をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=2:1〜1:3)で精製し、3−(4−ニトロフェニル)プロピル−2−エン−1−オール(2.16 g) を黄色粉末として得た。
(2)3−(4−ニトロフェニル)プロピル−2−エン−1−オール(0.67 g, 3.8 mmol)のメチレンクロライド(40 ml)溶液に、活性二酸化マンガン(5.01 g)を加え、室温で2時間反応させた。不溶物をセライトで濾過し、不溶物をクロロホルムで洗浄した。濾液を減圧濃縮し、得られた残査をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=6:1〜3:1)で精製し、3−(4−ニトロフェニル)プロペナ−ル(0.55 g)を淡黄色粉末として得た。
(3)3−(4−ニトロフェニル)プロペナ−ル(0.51 g, 2.9 mmol)のベンゼン(40 ml)溶液に、p−トルエンスルホン酸1水和物(0.059 g, 0.3 mmol)、2,2−ジメチルプロパン−1,3−ジオ−ル(0.36 g, 3.5 mmol)を加え、還流加熱下、5時間反応させた。反応液を室温まで冷却後、飽和炭酸水素ナトリウム水溶液(100 ml)を加え、酢酸エチル(100 ml)で2回抽出した。合わせた有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮し、得られた残査をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=9:1〜6:1)で精製し、5,5−ジメチル−2−[2−(4−ニトロフェニル)ビニル]−[1,3]ジオキサン(0.73 g)を無色粉末として得た。
(4)5,5−ジメチル−2−[2−(4−ニトロフェニル)ビニル]−[1,3]ジオキサン(0.64 g, 2.4 mmol)のメタノ−ル(20 ml)溶液に、5%パラジウム−活性炭 (0.26 g)を加え、水素雰囲気下、室温にて4時間攪拌した。TLC分析により原料の消失を確認した後に、セライトを用いて不溶物を濾過し、濾液を減圧濃縮した。得られた残査をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=4:1〜2:1)で精製し、4−[2−(5,5−ジメチル−[1,3]ジオキサン−2−イル)エチル]フェニルアミン(0.48 g)を無色粉末として得た。
(5)4−[2−(5,5−ジメチル−[1,3]ジオキサン−2−イル)エチル]フェニルアミン(0.32 g, 1.4 mmol)のメタノ−ル(10 ml)溶液に、N,N−ジメチルホルムアミドジメチルアセタ−ル(0.33 g, 2.8 mmol)を加え、100℃で4時間反応させた。反応液を室温まで冷却後、ヒドロキシルアミン1塩酸(0.14 g, 1.9 mmol)を加え、室温で一晩攪拌した。さらに塩化ヒドロキシアンモニウム(0.19 g, 2.8 mmol)を加え、室温で1時間、60℃で6.5時間反応させた。反応液を室温まで冷却後、飽和食塩水を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮して得られた残査をNHシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=2:1〜1:2)で精製し、標題化合物(0.25 g)を無色粉末として得た。
実施例8
N−[4−[3−(5,5−ジメチル−[1,3]ジオキサン−2−イル)プロピル]フェニル]−N'−ヒドロキシホルムアミジンの製造
エチル 4−ニトロシンナメ−トの代わりに4−(4−ニトロフェニル)ブチリックアシドを出発原料に用いて実施例7と同様な方法にて標題化合物を合成した。
実施例1〜8で合成した化合物の構造式を以下に示す。
上記表記載の化合物について、20−HETE産生阻害作用を試験した。
本試験はJ. Pharmacol. Exp. Ther., 第268巻, 474頁, 1994年に記載の方法に準拠して行った。
Claims (5)
- 式
(式中、R1は水素原子、C1−4アルキル基、C1−4アルコキシ基又はハロゲン原子を示し、AはC1−10アルキレン基又は式
(式中、m、n及びpは各々0〜4の整数を示す。)で表される基を示し、RはN,N−ジC1−6アルキルアミノ基、ジオキサニル基、C1−4アルキル基で置換されたジオキサニル基、C1−4アルコキシC1−4アルコキシ基又は式
(式中、s及びtは各々1〜4の整数を示し、Bはメチレン基、酸素原子、硫黄原子、窒素原子、C1−4アルキル基で置換された窒素原子、フェニル基で置換された窒素原子又はベンジル基で置換された窒素原子を示し、R2は水素原子又はC1−4アルキル基を示し、rは0〜2の整数を示す。)で表される基を示す。)で表されるN−ヒドロキシホルムアミジン誘導体又はその製薬学的に許容される塩。 - 請求の範囲1又は2記載のN−ヒドロキシホルムアミジン誘導体又はその製薬学的に許容される塩を有効成分とする医薬。
- 20−HETE産生酵素阻害剤である請求項3記載の医薬。
- 腎疾患、脳血管疾患又は循環器疾患治療薬である請求項3記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002266765 | 2002-09-12 | ||
JP2002266765 | 2002-09-12 | ||
PCT/JP2003/011603 WO2004024677A1 (ja) | 2002-09-12 | 2003-09-11 | N−ヒドロキシホルムアミジン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2004024677A1 JPWO2004024677A1 (ja) | 2006-01-05 |
JP4389271B2 true JP4389271B2 (ja) | 2009-12-24 |
Family
ID=31986662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004535940A Expired - Fee Related JP4389271B2 (ja) | 2002-09-12 | 2003-09-11 | N−ヒドロキシホルムアミジン誘導体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7288566B2 (ja) |
JP (1) | JP4389271B2 (ja) |
CN (1) | CN1293049C (ja) |
AU (1) | AU2003262069A1 (ja) |
HK (1) | HK1081943A1 (ja) |
WO (1) | WO2004024677A1 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1250209C (zh) * | 1999-11-01 | 2006-04-12 | 大正制药株式会社 | 20-羟基二十碳四烯酸合成酶抑制剂 |
AU2001241084A1 (en) | 2000-03-13 | 2001-09-24 | Taisho Pharmaceutical Co. Ltd. | Imidazolylbenzophenone derivatives |
JP2001354656A (ja) | 2000-06-15 | 2001-12-25 | Taisho Pharmaceut Co Ltd | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 |
JP2001354658A (ja) | 2000-06-15 | 2001-12-25 | Taisho Pharmaceut Co Ltd | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 |
WO2001096309A1 (fr) | 2000-06-15 | 2001-12-20 | Taisho Pharmaceutical Co., Ltd. | Derives hydroxyformamidine et medicaments les contenant |
-
2003
- 2003-09-11 AU AU2003262069A patent/AU2003262069A1/en not_active Abandoned
- 2003-09-11 CN CNB038217953A patent/CN1293049C/zh not_active Expired - Fee Related
- 2003-09-11 WO PCT/JP2003/011603 patent/WO2004024677A1/ja active Application Filing
- 2003-09-11 JP JP2004535940A patent/JP4389271B2/ja not_active Expired - Fee Related
- 2003-09-11 US US10/527,716 patent/US7288566B2/en not_active Expired - Fee Related
-
2006
- 2006-02-20 HK HK06102222A patent/HK1081943A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPWO2004024677A1 (ja) | 2006-01-05 |
US20060004078A1 (en) | 2006-01-05 |
CN1681775A (zh) | 2005-10-12 |
US7288566B2 (en) | 2007-10-30 |
WO2004024677A1 (ja) | 2004-03-25 |
CN1293049C (zh) | 2007-01-03 |
AU2003262069A1 (en) | 2004-04-30 |
HK1081943A1 (en) | 2006-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018188482A (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
AU2020323429A1 (en) | Urea compound for antagonizing LPA1 receptor | |
RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
BR112020012629A2 (pt) | estimulantes de sgc | |
CZ2003467A3 (cs) | Fenoxybenzylaminové deriváty jako selektivní inhibitory reuptake serotoninu | |
WO2006134487A1 (en) | 3-phenylazetidine derivatives as dopamine agonists | |
FR2927330A1 (fr) | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii | |
RU2008129623A (ru) | Ингибиторы ccr9 активности | |
RU2010132254A (ru) | Некоторые химические структуры, композиции и способы | |
JP6228667B2 (ja) | 新規な抗真菌性オキソジヒドロピリジンカルボヒドラジド誘導体 | |
EP2867215B1 (en) | Tetrazole derivatives and their use as potassium channel modulators | |
JP2009507899A (ja) | 飽和o−複素環により置換されたアルカン酸アミド | |
JP4904659B2 (ja) | ヒドロキシホルムアミジン誘導体及びそれらを含む医薬 | |
JP4389271B2 (ja) | N−ヒドロキシホルムアミジン誘導体 | |
TW200948805A (en) | Enol carbamate derivatives as modulators of fatty acid amide hydrolase | |
Holsworth et al. | Discovery of novel non-peptidic ketopiperazine-based renin inhibitors | |
PL207487B1 (pl) | Pochodna aminobenzofenonu o wzorze I, jej zastosowanie i kompozycja zawierająca ten związek | |
JP2005272446A (ja) | 20−hete産生酵素阻害剤 | |
Yamaguchi et al. | The P1 N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin | |
TNSN08287A1 (en) | 3,5-substituted piperidine compounds as renin inhibitors | |
KR20090090347A (ko) | Trpv1 수용체 길항제인 o-치환된-디벤질 우레아-유도체 | |
KR100819322B1 (ko) | 20-히드록시에이코사테트라엔산 생산 저해제 | |
EA200970496A1 (ru) | Соединения 2-алкилиндазола для лечения некоторых расстройств цнс |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060911 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090914 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090927 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121016 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121016 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121016 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131016 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |